CRISPR Therapeutics AG (CRSP) Stock Grade

About CRISPR Therapeutics AG's fundamentals

CRISPR Therapeutics is a $4.7 billion biotechnology company that reported significant financial challenges in its latest annual statement, including a substantial net loss and a negative net margin of -16,569.8%. The company experienced a steep 90% year-over-year revenue decline, indicating a major contraction in its commercial operations. CRISPR does not pay dividends, and the company's pre-profitability status means standard valuation metrics like P/E ratio and return on equity are not applicable. These metrics reflect the company's current position as a loss-making enterprise, typical of earlier-stage biotechnology firms, though the magnitude of the revenue decline and losses warrant close monitoring.